Analyzing Envista (NYSE:NVST) and BioLife Solutions (NASDAQ:BLFS)

BioLife Solutions (NASDAQ:BLFS) and Envista (NYSE:NVST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation & Earnings

This table compares BioLife Solutions and Envista”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$82.25 million	14.82	-$20.18 million	($0.07)	-361.57
Envista	$2.51 billion	1.48	-$1.12 billion	$0.09	250.36

BioLife Solutions has higher earnings, but lower revenue than Envista. BioLife Solutions is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 0.7% of Envista shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Envista’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-3.20%	0.97%	0.87%
Envista	0.58%	5.90%	3.25%

Volatility & Risk

BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Envista has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioLife Solutions and Envista, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1	1	4	0	2.50
Envista	2	8	5	1	2.31

BioLife Solutions currently has a consensus target price of $32.00, indicating a potential upside of 26.43%. Envista has a consensus target price of $21.77, indicating a potential downside of 3.39%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, research analysts plainly believe BioLife Solutions is more favorable than Envista.

Summary

Envista beats BioLife Solutions on 8 of the 15 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.